6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
) O
are O
acne O
, O
application O
site O
reaction O
, O
abnormal O
lab O
tests O
, O
and O
prostatic O
disorders O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AbbVie O
Inc O
. O
at O
1-800-633-9110 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Clinical O
Trials O
in O
Hypogonadal O
Men O
Table O
1 O
shows O
the O
incidence O
of O
all O
adverse O
events O
judged O
by O
the O
investigator O
to O
be O
at O
least O
possibly O
related O
to O
treatment O
with O
AndroGel O
1 O
% O
and O
reported O
by O
> O
1 O
% O
of O
patients O
in O
a O
180 O
Day O
, O
Phase O
3 O
study O
. O

Table O
1 O
: O
Adverse O
Events O
Possibly O
, O
Probably O
or O
Definitely O
Related O
to O
Use O
of O
AndroGel O
1 O
% O
in O
the O
180-Day O
Controlled O
Clinical O
Trial O
* O
Lab B-NonOSE_AE
test I-NonOSE_AE
abnormal I-NonOSE_AE
occurred O
in O
nine O
patients O
with O
one O
or O
more O
of O
the O
following O
events O
reported O
: O
elevated B-OSE_Labeled_AE
hemoglobin O
or O
hematocrit I-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
total I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
. O

** O
Prostate B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
included O
five O
patients O
with O
enlarged B-OSE_Labeled_AE
prostate I-OSE_Labeled_AE
, O
one O
with O
BPH B-OSE_Labeled_AE
, O
and O
one O
with O
elevated B-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
results O
. O

*** O
Testis B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
were O
reported O
in O
two O
patients O
: O
one O
with O
left B-OSE_Labeled_AE
varicocele I-OSE_Labeled_AE
and O
one O
with O
slight O
sensitivity B-OSE_Labeled_AE
of I-OSE_Labeled_AE
left I-OSE_Labeled_AE
testis I-OSE_Labeled_AE
. O

Adverse O
Event O
Dose O
of O
AndroGel O
1 O
% O
50 O
mg O
75 O
mg O
100 O
mg O
N O
= O
77 O
N O
= O
40 O
N O
= O
78 O
Acne B-OSE_Labeled_AE
1 O
% O
3 O
% O
8 O
% O
Alopecia B-OSE_Labeled_AE
1 O
% O
0 O
% O
1 O
% O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
5 O
% O
3 O
% O
4 O
% O
Asthenia B-OSE_Labeled_AE
0 O
% O
3 O
% O
1 O
% O
Depression B-OSE_Labeled_AE
1 O
% O
0 O
% O
1 O
% O
Emotional B-OSE_Labeled_AE
Lability I-OSE_Labeled_AE
0 O
% O
3 O
% O
3 O
% O
Gynecomastia B-OSE_Labeled_AE
1 O
% O
0 O
% O
3 O
% O
Headache B-OSE_Labeled_AE
4 O
% O
3 O
% O
0 O
% O
Hypertension B-OSE_Labeled_AE
3 O
% O
0 O
% O
3 O
% O
Lab B-NonOSE_AE
Test I-NonOSE_AE
Abnormal I-NonOSE_AE
* O
6 O
% O
5 O
% O
3 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
0 O
% O
3 O
% O
1 O
% O
Nervousness B-OSE_Labeled_AE
0 O
% O
3 O
% O
1 O
% O
Pain B-OSE_Labeled_AE
Breast I-OSE_Labeled_AE
1 O
% O
3 O
% O
1 O
% O
Prostate B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
* I-OSE_Labeled_AE
* I-OSE_Labeled_AE
3 O
% O
3 O
% O
5 O
% O
Testis B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
*** O
3 O
% O
0 O
% O
0 O
% O
Other O
less O
common O
adverse O
reactions O
, O
reported O
in O
fewer O
than O
1 O
% O
of O
patients O
included O
: O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
discolored B-OSE_Labeled_AE
hair I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
impaired B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
penis B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
and O
vasodilation B-OSE_Labeled_AE
. O

In O
this O
180 O
day O
clinical O
trial O
, O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
site I-OSE_Labeled_AE
of I-OSE_Labeled_AE
application I-OSE_Labeled_AE
were O
reported O
with O
AndroGel O
1 O
% O
, O
but O
none O
was O
severe O
enough O
to O
require O
treatment O
or O
discontinuation O
of O
drug O
. O

Six O
patients O
( O
4 O
% O
) O
in O
this O
trial O
had O
adverse O
events O
that O
led O
to O
discontinuation O
of O
AndroGel O
1 O
% O
. O

These O
events O
included O
: O
cerebral B-NonOSE_AE
hemorrhage I-NonOSE_AE
, O
convulsion B-NonOSE_AE
( O
neither O
of O
which O
were O
considered O
related O
to O
AndroGel O
1 O
% O
administration O
) O
, O
depression B-OSE_Labeled_AE
, O
sadness B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
prostate I-OSE_Labeled_AE
specific I-OSE_Labeled_AE
antigen I-OSE_Labeled_AE
, O
and O
hypertension B-OSE_Labeled_AE
. O

No O
AndroGel O
1 O
% O
patient O
discontinued O
due O
to O
skin B-NonOSE_AE
reactions I-NonOSE_AE
. O

In O
a O
separate O
uncontrolled O
pharmacokinetic O
study O
of O
10 O
patients O
, O
two O
had O
adverse O
events O
associated O
with O
AndroGel O
1 O
% O
; O
these O
were O
asthenia B-OSE_Labeled_AE
and O
depression B-OSE_Labeled_AE
in O
one O
patient O
and O
increased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
and O
hyperkinesia B-OSE_Labeled_AE
in O
the O
other O
. O

In O
a O
3 O
year O
, O
flexible O
dose O
, O
extension O
study O
, O
the O
incidence O
of O
all O
adverse O
events O
judged O
by O
the O
investigator O
to O
be O
at O
least O
possibly O
related O
to O
treatment O
with O
AndroGel O
1 O
% O
and O
reported O
by O
> O
1 O
% O
of O
patients O
is O
shown O
in O
Table O
2 O
. O

Table O
2 O
: O
Adverse O
Events O
Possibly O
, O
Probably O
or O
Definitely O
Related O
to O
Use O
of O
AndroGel O
1 O
% O
in O
the O
3 O
Year O
, O
Flexible O
Dose O
, O
Extension O
Study O
Adverse O
Event O
Percent O
of O
Subjects O
( O
N O
= O
162 O
) O
+ O
Lab B-NonOSE_AE
test I-NonOSE_AE
abnormal I-NonOSE_AE
occurred O
in O
15 O
patients O
with O
one O
or O
more O
of O
the O
following O
events O
reported O
: O
elevated B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
hemoglobin O
or O
hematocrit I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
ratio I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
. O

* O
Urinary B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
included O
nocturia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
hesitancy I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
and O
weak B-OSE_Labeled_AE
urinary I-OSE_Labeled_AE
stream I-OSE_Labeled_AE
. O

** O
Testis B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
included O
three O
patients O
. O

There O
were O
two O
with O
a O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
palpable I-OSE_Labeled_AE
testis I-OSE_Labeled_AE
and O
one O
with O
slight O
right B-OSE_Labeled_AE
testicular I-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
. O

Lab B-NonOSE_AE
Test I-NonOSE_AE
Abnormal I-NonOSE_AE
+ O
9.3 O
Skin B-OSE_Labeled_AE
dry I-OSE_Labeled_AE
1.9 O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
5.6 O
Acne B-OSE_Labeled_AE
3.1 O
Pruritus B-OSE_Labeled_AE
1.9 O
Enlarged B-OSE_Labeled_AE
Prostate I-OSE_Labeled_AE
11.7 O
Carcinoma B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Prostate I-OSE_Labeled_AE
1.2 O
Urinary B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
* O
3.7 O
Testis B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
** O
1.9 O
Gynecomastia B-OSE_Labeled_AE
2.5 O
Anemia B-OSE_Labeled_AE
2.5 O
Two O
patients O
reported O
serious O
adverse O
events O
considered O
possibly O
related O
to O
treatment O
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
and O
prostate B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
requiring O
a O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
. O

Discontinuation O
for O
adverse O
events O
in O
this O
study O
included O
: O
two O
patients O
with O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
one O
with O
kidney B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
five O
with O
prostate B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
including O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
in O
4 O
patients O
, O
and O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
with O
prostate B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
in O
a O
fifth O
patient O
) O
. O

Increases O
in O
Serum O
PSA O
Observed O
in O
Clinical O
Trials O
of O
Hypogonadal O
Men O
During O
the O
initial O
6-month O
study O
, O
the O
mean O
change O
in O
PSA B-OSE_Labeled_AE
values I-OSE_Labeled_AE
had O
a O
statistically O
significant O
increase I-OSE_Labeled_AE
of O
0.26 O
ng/mL O
. O

Serum O
PSA O
was O
measured O
every O
6 O
months O
thereafter O
in O
the O
162 O
hypogonadal B-Not_AE_Candidate
men O
on O
AndroGel O
1 O
% O
in O
the O
3-year O
extension O
study O
. O

There O
was O
no O
additional O
statistically O
significant O
increase B-NonOSE_AE
observed O
in O
mean O
PSA I-NonOSE_AE
from O
6 O
months O
through O
36 O
months O
. O

However O
, O
there O
were O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
observed O
in O
approximately O
18 O
% O
of O
individual O
patients O
. O

The O
overall O
mean O
change O
from O
baseline O
in O
serum O
PSA O
values O
for O
the O
entire O
group O
from O
month O
6 O
to O
36 O
was O
0.11 O
ng/mL O
. O

Twenty-nine O
patients O
( O
18 O
% O
) O
met O
the O
per-protocol O
criterion O
for O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
, O
defined O
as O
> O
2X O
the O
baseline O
or O
any O
single O
serum O
PSA B-OSE_Labeled_AE
> I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
. O

Most O
of O
these O
( O
25/29 O
) O
met O
this O
criterion O
by O
at O
least O
doubling B-OSE_Labeled_AE
of I-OSE_Labeled_AE
their I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
from O
baseline O
. O

In O
most O
cases O
where O
PSA B-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
doubled I-OSE_Labeled_AE
( O
22/25 O
) O
, O
the O
maximum O
serum O
PSA O
value O
was O
still O
< O
2 O
ng/mL O
. O

The O
first O
occurrence O
of O
a O
pre-specified O
, O
post-baseline O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
was O
seen O
at O
or O
prior O
to O
Month O
12 O
in O
most O
of O
the O
patients O
who O
met O
this O
criterion O
( O
23 O
of O
29 O
; O
79 O
% O
) O
. O

Four O
patients O
met O
this O
criterion O
by O
having O
a O
serum O
PSA B-OSE_Labeled_AE
> I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
and O
in O
these O
, O
maximum O
serum O
PSA O
values O
were O
6.2 O
ng/mL O
, O
6.6 O
ng/mL O
, O
6.7 O
ng/mL O
, O
and O
10.7 O
ng/mL O
. O

In O
two O
of O
these O
patients O
, O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
was O
detected O
on O
biopsy O
. O

The O
first O
patient O
's O
PSA O
levels O
were O
4.7 O
ng/mL O
and O
6.2 O
ng/mL O
at O
baseline O
and O
at O
Month O
6/Final O
, O
respectively O
. O

The O
second O
patient O
's O
PSA O
levels O
were O
4.2 O
ng/mL O
, O
5.2 O
ng/mL O
, O
5.8 O
ng/mL O
, O
and O
6.6 O
ng/mL O
at O
baseline O
, O
Month O
6 O
, O
Month O
12 O
, O
and O
Final O
, O
respectively O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
AndroGel O
1 O
% O
. O

Because O
the O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
( O
Table O
3 O
) O
. O

Table O
3 O
: O
Adverse O
Drug O
Reactions O
from O
Postmarketing O
Experience O
of O
AndroGel O
1 O
% O
by O
MedDRA O
System O
Organ O
Class O
Blood B-NonOSE_AE
and I-NonOSE_AE
the I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Elevated B-OSE_Labeled_AE
Hgb I-OSE_Labeled_AE
, O
Hct O
( O
polycythemia B-OSE_Labeled_AE
) O
Cardiovascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hirsutism B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Nausea B-OSE_Labeled_AE
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
: O
Asthenia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
Genitourinary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Impaired B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
e.g O
. O

transaminases O
, O
elevated B-OSE_Labeled_AE
GGTP O
, O
bilirubin I-OSE_Labeled_AE
) O
Investigations B-NonOSE_AE
: O
Elevated B-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
, O
electrolyte B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( O
nitrogen O
, O
calcium O
, O
potassium O
, O
phosphorus O
, O
sodium O
) O
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
lipids I-OSE_Labeled_AE
( O
hyperlipidemia B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
) O
, O
impaired B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
tolerance I-OSE_Labeled_AE
, O
fluctuating B-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
( I-NonOSE_AE
cysts I-NonOSE_AE
and I-NonOSE_AE
polyps I-NonOSE_AE
) O
: O
Prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
Headache B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
apnea I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Depression B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
: O
Gynecomastia B-OSE_Labeled_AE
, O
mastodynia B-OSE_Labeled_AE
, O
prostatic B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
, O
oligospermia B-OSE_Labeled_AE
, O
priapism B-OSE_Labeled_AE
( O
frequent O
or O
prolonged B-OSE_Labeled_AE
erections I-OSE_Labeled_AE
) O
Respiratory B-NonOSE_AE
disorders I-NonOSE_AE
: O
Dyspnea B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
pruritus B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
discolored B-OSE_Labeled_AE
hair I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
) O
, O
sweating B-OSE_Labeled_AE
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypertension B-OSE_Labeled_AE
, O
vasodilation B-OSE_Labeled_AE
( O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
) O
, O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
Secondary O
Exposure O
to O
Testosterone O
in O
Children O
Cases O
of O
secondary B-OSE_Labeled_AE
exposure I-OSE_Labeled_AE
to O
testosterone O
resulting O
in O
virilization O
of O
ch O
ildren B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_Labeled_AE O
have O
been O
reported O
in O
postmarket O
surveillance O
. O

Signs O
and O
symptoms O
of O
these O
reported O
cases O
have O
included O
enlargement B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
clitoris I-NonOSE_AE
( O
with O
surgical O
intervention O
) O
or O
the O
penis O
, O
development B-NonOSE_AE
of I-NonOSE_AE
pubic I-NonOSE_AE
hair I-NonOSE_AE
, O
increased B-NonOSE_AE
erections I-NonOSE_AE
and O
libido O
, O
aggressive B-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
advanced B-NonOSE_AE
bone I-NonOSE_AE
age I-NonOSE_AE
. O

In O
most O
cases O
with O
a O
reported O
outcome O
, O
these O
signs O
and O
symptoms O
were O
reported O
to O
have O
regressed O
with O
removal O
of O
the O
testosterone O
gel O
exposure O
. O

In O
a O
few O
cases O
, O
however O
, O
enlarged B-NonOSE_AE
genitalia I-NonOSE_AE
did O
not O
fully O
return O
to O
age O
appropriate O
normal O
size O
, O
and O
bone B-NonOSE_AE
age I-NonOSE_AE
remained I-NonOSE_AE
modestly I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
chronological I-NonOSE_AE
age I-NonOSE_AE
. O

In O
some O
of O
the O
cases O
, O
direct O
contact O
with O
the O
sites O
of O
application O
on O
the O
skin O
of O
men O
using O
testosterone O
gel O
was O
reported O
. O

In O
at O
least O
one O
reported O
case O
, O
the O
reporter O
considered O
the O
possibility O
of O
secondary O
exposure O
from O
items O
such O
as O
the O
testosterone O
gel O
user O
's O
shirts O
and/or O
other O
fabric O
, O
such O
as O
towels O
and O
sheets O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

